What is 9 Meters Biopharma Financial Strength?
9 Meters Biopharma has the Financial Strength Rank of 0.
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors:
1. The debt burden that the company has as measured by its
Interest Coverage (current year). The higher, the better.
2. Debt to revenue ratio. The lower, the better.
3.
Altman Z-Score.
9 Meters Biopharma did not have earnings to cover the interest expense.
As of today, 9 Meters Biopharma's Altman Z-Score is 0.00.
Competitive Comparison of 9 Meters Biopharma's Financial Strength
For the Biotechnology subindustry, 9 Meters Biopharma's Financial Strength, along with its competitors' market caps and Financial Strength data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
9 Meters Biopharma's Financial Strength Distribution in the Biotechnology Industry
For the Biotechnology industry and Healthcare sector, 9 Meters Biopharma's Financial Strength distribution charts can be found below:
* The bar in red indicates where 9 Meters Biopharma's Financial Strength falls into.
9 Meters Biopharma Financial Strength Calculation
GuruFocus Financial Strength Rank measures how strong a company's financial situation is. It is based on these factors
A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.
1. The debt burden that the company has as measured by its Interest Coverage (current year). The higher, the better.
Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.
Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense:
9 Meters Biopharma's Interest Expense for the
months ended in Mar. 2023 was $-0.75 Mil. Its Operating Income for the
months ended in Mar. 2023 was $-12.79 Mil. And its Long-Term Debt & Capital Lease Obligation for the quarter that ended in Mar. 2023 was $0.04 Mil.
9 Meters Biopharma's Interest Coverage for the quarter that ended in Mar. 2023 is
| 9 Meters Biopharma did not have earnings to cover the interest expense. |
The higher the ratio, the stronger the company's financial strength is.
2. Debt to revenue ratio. The lower, the better.
9 Meters Biopharma's Debt to Revenue Ratio for the quarter that ended in Mar. 2023 is
3. Altman Z-Score.
Z-Score model is an accurate forecaster of failure up to two years prior to distress. It can be considered the assessment of the distress of industrial corporations.
The zones of discrimination were as such:
When Z-Score is less than 1.81, it is in Distress Zones.
When Z-Score is greater than 2.99, it is in Safe Zones.
When Z-Score is between 1.81 and 2.99, it is in Grey Zones.
9 Meters Biopharma has a Z-score of 0.00, indicating it is in Distress Zones. This implies bankrupcy possibility in the next two years.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
9 Meters Biopharma (9 Meters Biopharma) Business Description
Traded in Other Exchanges
N/A
Address
4509 Creedmoor Road, Suite 201, Raleigh, NC, USA, 27612
9 Meters Biopharma Inc is a clinical-stage biopharmaceutical company focused on rare and unmet needs in gastroenterology. Its pipeline includes drug candidates for short bowel syndrome (SBS), celiac disease, and three early-stage candidates for undisclosed rare diseases and/or unmet needs. Its products include NM-002, Larazotide, NM-003, and others.
Executives
| Bethany Sensenig |
officer: Chief Financial Officer |
C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615 |
| John Temperato |
director, officer: Chief Executive Officer |
C/O MELINTA THERAPEUTICS,INC., 300 GEORGE STREET, SUITE 301, NEW HAVEN CT 06511 |
| Mark A Sirgo |
director |
C/O BIODELIVERY SCIENCES INTERNATIONAL, 801 CORPORATE CENTER DRIVE -SUITE 210, RALEIGH NC 27607 |
| Michael T. Constantino |
director |
C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615 |
| Samantha Ventimiglia |
director |
C/O 9 METERS BIOPHARMA, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615 |
| Edward J Sitar |
officer: Chief Financial Officer |
39 FLAMING ARROW ROAD, MAHWAH NJ 07430 |
| Orbimed Israel Biofund Gp Limited Partnership |
10 percent owner |
601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 1022-4629 |
| Yehuda Michael Rice |
director |
155 WALNUT STREET, ENGLEWOOD NJ 07631 |
| Nissim Darvish |
director, 10 percent owner |
C/O INNOVATE BIOPHARMACEUTICALS, INC., 8480 HONEYCUTT ROAD, SUITE 120, RALEIGH NC 27615 |
| Orbimed Israel Gp Ltd. |
10 percent owner |
601 LEXINGTON AVENUE, 54TH FLOOR, NEW YORK NY 10022-4629 |
| Sandeep Laumas |
director, officer: Executive Chairman |
8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615 |
| Jay P. Madan |
director, officer: President |
8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615 |
| Roy Proujansky |
director |
144 PAU NEL DRIVE, LANDENBERG PA 19350 |
| Christopher P. Prior |
director, officer: Chief Executive Officer |
8480 HONEYCUTT RD, SUITE 200, RALEIGH NC 27615 |
| June Sherie Almenoff |
officer: COO and Chief Medical Officer |
C/O BRAINSTORM CELL THERAPEUTICS INC., 1325 AVENUE OF AMERICAS 28TH FLOOR, NEW YORK NY 10019 |
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
Portfolio Contest
NMTRQ has been successfully added to your